Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Beyond Humira: How AbbVie Plans To Hold Its Immunology Leadership Reign

This article was originally published in The Pink Sheet Daily

Executive Summary

AbbVie detailed plans for a pair of late-stage immunology candidates – an anti-IL-23 drug and a JAK1 inhibitor – that it says point to a bright future in immunology after Humira's patent expires during an R&D day.


Related Content

AbbVie’s Cancer Expansion Is Paying Off


Related Companies